VUNO

The deep learning model is the product. DeepCARS converts four routinely charted vital signs into a 0 to 100 risk score, and there is no hardware, monitoring device, or services layer being sold alongside it. The company's own framing makes the centrality explicit: this was the first biosignal based AI medical device to commercialize in a Korean market where medical AI research had been almost entirely image analysis.

Produces a risk score for a rapid response team to act on, so the human decides whether and how to intervene. The oversight question here is specific to early warning systems and worth naming: a deterioration score that fires too often produces alarm fatigue and gets ignored, while one tuned too conservatively misses patients. The company positions the tool as enabling timely intervention rather than triggering automated escalation, and the deployment context is general wards where nursing staff, not the algorithm, mobilize the response.

Inputs and outputs are stated with precision, four named vital signs producing a 0 to 100 score over a 24 hour horizon, and discrimination is published rather than asserted: AUROC 0.860 on internal validation and 0.905 on external validation from a multicenter study of 173,368 patients. Publishing external validation performance separately from internal, and having the external figure be the higher one, is a meaningful disclosure. Model architecture detail beyond deep learning on vital sign sequences is not published, and no calibration or alert rate data was located, which matters more than discrimination for an early warning system.

Among the better evidenced deterioration prediction tools in this index, and the evidence is genuinely independent of the vendor's marketing. Peer reviewed publications appear in Resuscitation, the Journal of the American Heart Association, and Critical Care Medicine, with a multicenter validation of 173,368 patients. Crucially there is a PROSPECTIVE multicenter validation published in Critical Care in 2023, co-authored across Seoul National University Hospital, Seoul National University Bundang, Inha, and Dong-A University Hospital, testing prediction of cardiac arrest or unplanned ICU transfer and reporting superiority over traditional early warning scores. Prospective evidence is rare in this category, where most tools rest on retrospective cohorts. Deployment across 48,000 plus beds adds real world scale, though all published evidence is from Korean cohorts, so US generalization is untested.

No specific PHI handling or data governance framework was located. The product reads vital signs continuously from the EMR, which is a narrow but continuous data feed, and terms are not published.

No HIPAA or BAA commitment was located. As a Korea headquartered vendor now selling into US hospitals through a Massachusetts office, a US buyer should establish business associate terms and confirm where inference runs.

No SOC 2, ISO 27001, or equivalent attestation and no trust center were located in the materials reviewed.

Approved and commercially deployed at scale in its home market, not yet cleared in the US. Korea's MFDS granted approval in 2021 after designating it a breakthrough medical device, and the product is in routine clinical use across 48,000 plus Korean hospital beds. In the US it holds FDA Breakthrough Device Designation granted 2023 and is pursuing 510(k) clearance, with US clinical studies underway. Applying the index rule consistently, Breakthrough Device Designation is a review pathway commitment rather than a clearance, so a US hospital cannot deploy this clinically today. Graded C on the same basis as Genomate, Nucs, Modella, and Valar. The Korean approval is real regulatory authorization, just not US authorization.

Multicenter validation across several independent Korean tertiary hospitals addresses site level generalization, and the prospective design tests the model in live conditions rather than on curated retrospective data. What is absent is any demographic subgroup analysis, and the concern is concrete for this product class: vital sign based deterioration models are known to perform differently across age, sex, and comorbidity profiles, and the entire published evidence base is drawn from a single national population, which leaves performance in a more heterogeneous US population undocumented.

Integration is the deployment mechanism rather than a feature, since the model consumes vital signs directly from the electronic medical record and returns scores into ward monitoring workflows. The company frames the reliance on only four routinely collected vital signs as itself an adoption advantage, because no new instrumentation, device, or documentation burden is required, which is a genuine interoperability argument. No named EHR connector list or API documentation was located, and Korean hospital EMR integration does not automatically transfer to Epic or Oracle Health environments.

No hosting, tenancy, or data residency terms were located. For a Korea headquartered vendor processing continuous inpatient vital sign data for US hospitals, where inference runs is a material question that is not addressed publicly.

No pricing is published. The company is listed on the Korean exchange, which brings financial disclosure obligations absent from private competitors and gives a buyer some visibility into vendor stability, but nothing on per bed, per hospital, or subscription cost. US pricing is likely unsettled given the product is pre clearance there.

Deliberately narrow: general hospital wards, predicting cardiac arrest and unplanned ICU transfer in admitted inpatients. That is a high value setting, since deterioration on general wards is where rapid response teams are supposed to intervene and frequently do not in time, but it does not extend to ICU, emergency department triage, or outpatient monitoring. The broader company portfolio includes imaging products, though DeepCARS is the flagship and the basis of this record.